SecBot SecBot
6-K ·Filed Aug 17, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001654954-26-007681
Actionable Insight ▲ Bullish

The Enhertu DESTINY-Lung04 win is the dominant catalyst, expect positive analyst attention and potential for regulatory submissions in 1L HER2-mutant NSCLC. The volrustomig failure is a pipeline setback but manageable for a diversified mega-cap. Monitor upcoming medical meeting presentations for DESTINY-Lung04 data details and regulatory timelines. The net read-through is modestly positive for AZN.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

AZN drug pipeline →

trastuzumab deruxtecan

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and commercialized (since 2019 for initial indication)
Next catalyst
None dated

What to watchFor investors in AZN, Enhertu is a mature commercial asset driving growth, not a binary catalyst. The next watchpoint is the readout of DESTINY-Gastric04 (Phase 3 in HER2+ gastric cancer, estimated primary completion Aug 2026). For VIVS/VivoSim Labs, the drug is not theirs, they merely tested it on a safety platform, so any trading thesis tied to trastuzumab deruxtecan should not involve VIVS stock.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$156.89
T+0 close · Aug 17, 2026 · via day close
Latest settled
+20.72%
T+60 · $189.39
Vs SPY
+23.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $156.89entry
  2. T+1 · 3mo ago +2.05%α +2.72% · $160.10
  3. T+5 · 3mo ago +6.26%α +7.45% · $166.71
  4. T+20 · 2mo ago +4.39%α +5.92% · $163.78
  5. T+60 · 6d ago +20.72%α +23.48% · $189.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca reported two clinical trial updates on the same day: (1) Enhertu (trastuzumab deruxtecan) achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs standard of care in the DESTINY-Lung04 Phase III trial for 1st-line HER2-mutant advanced NSCLC, supporting label expansion into earlier treatment; (2) the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in 1st-line metastatic NSCLC (PD-L1 <50%) was discontinued after an IDMC concluded it was unlikely to meet dual primary endpoints of PFS or OS in the PD-L1 <1% population. The Enhertu win is a clear pipeline positive for a key growth asset, while the volrustomig failure is a setback for the IO bispecific pipeline but involves an earlier-stage asset with limited near-term revenue contribution. On balance, the Enhertu catalyst dominates for a $242B mega-cap with a diversified pipeline, making the net read-through modestly bullish.

Key Facts

  • Enhertu (trastuzumab deruxtecan) demonstrated statistically significant and clinically meaningful improvement in PFS vs global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) in the DESTINY-Lung04 Phase III trial for 1st-line HER2-mutant advanced NSCLC.
  • DESTINY-Lung04 enrolled 454 patients across Asia, Europe and North America; the trial will continue to evaluate secondary endpoints including overall survival.
  • Enhertu is already approved in >80 countries for previously treated HER2-mutant metastatic NSCLC; this data supports potential label expansion to 1st-line treatment.
  • AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in 1st-line mNSCLC (PD-L1 <50%) after an IDMC concluded it was unlikely to meet dual primary endpoints of PFS or OS in the PD-L1 <1% population.
  • eVOLVE-Lung02 enrolled 895 patients across 25 countries; other Phase III volrustomig trials in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma continue as planned.
  • No new safety signals were identified in either trial.

Financial Impact

Enhertu is a key growth driver for AstraZeneca's oncology portfolio; a 1st-line label expansion in HER2-mutant NSCLC (2-4% of NSCLC patients) could meaningfully expand the addressable patient population. Volrustomig is an early-stage pipeline asset with no approved indications, so the trial discontinuation has no direct revenue impact.

revenuepipeline value

Risk Factors

  • DESTINY-Lung04 overall survival data are not yet mature; the PFS benefit may not translate to an OS advantage.
  • Regulatory approval for 1st-line label expansion is not guaranteed and timelines are uncertain.
  • Volrustomig's failure in NSCLC raises questions about the broader bispecific IO pipeline, though other indications continue.
  • Enhertu's safety profile includes interstitial lung disease risk, which could affect the benefit-risk assessment in earlier treatment settings.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (AZN), Batch item 10001654954-26-007681
Document: 0001654954-26-007681-index-headers.html0001654954-26-007679
Document: 0001654954-26-007681-index.html0001654954-26-007681
Document: 0001654954-26-007681.txt0001654954-26-007681
6-K Filing (AZN), Batch item 50001654954-26-007679
Document: 0001654954-26-007679-index-headers.html0001654954-26-007681
Document: 0001654954-26-007679-index.html0001654954-26-007681
Document: 0001654954-26-007679.txt0001654954-26-007681

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026